 MALVERN, Pa., Jan. 14, 2021 GLOBE NEWSWIRE -- TELA Bio, Inc. TELA Nasdaq: TELA, a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2020. 